LOG IN
SIGN UP
Study Suggests Whole-Plant Medicinal Cannabis Could Be More Effective Than CBD In Epilepsy Treatment
Epileptic seizure frequency fell by an average of 86% among ten children treated with whole-plant medicinal cannabis, reveals a case series published in the open-access journal BMJ Paediatrics Open.
Benzinga · 12/15/2021 21:43
GW Pharma's Epidyolex approved in U.K. for seizures due to tuberous sclerosis complex
GW Pharmaceuticals, now part of Jazz Pharmaceuticals (NASDAQ:JAZZ) announces that the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) has approved a new indication for GW's cannabidiol (Epidyolex/Epidiolex) as an adjunctive treatment
Seekingalpha · 08/10/2021 08:50
Does Big Business Provide A Better Look Into Cannabis Reform Than Capitol Hill? Operators Believe So.
Cannabis operators and executives tell Benzinga that the movement of private and public companies may serve as a better indicator of regulatory activity than the federal government. At the very least, they say that the industry has made advancements so far...
Benzinga · 07/29/2021 13:20
Biotech M&A may heat up with potential targets Horizon Therapeutics, Arrowhead Pharma, analyst says
janiecbros/E+ via Getty Images Biotech M&A is poised to heat up again as shares of the SPDR S&P Biotech’s (XBI) have fallen about 25% from their February highs, according to
Seekingalpha · 07/11/2021 13:00
Nextleaf Solutions Forges Unique Path in the Cannabis Industry with its IP Strategy
As the United States federal government continues to look at the option of national cannabis legalization, there are now only two states which haven't been given limited access. As a result of the U.S.
Benzinga · 07/07/2021 12:48
Mid-size pharmaceutical firms lead bigger rivals in acquisitions this year
Zhanna Hapanovich/iStock via Getty Images Concerned over high premiums of targets, the large-cap pharmaceutical companies have taken a backseat in acquisitions this year as they focused on repayment of debt
Seekingalpha · 07/07/2021 10:49
The Week In Cannabis: Justice Clarence Thomas, Mexico's Decriminalization, Apple's Policy Changes, Tilray And More
Below is a recap of the main news related to the cannabis industry and markets for the week of June 28, 2021.
Benzinga · 07/06/2021 20:04
A Complete List Of NYSE And NASDAQ-Listed Cannabis Companies (Updated)
As the cannabis industry keeps pushing forward, more companies are moving to list their stock on a major U.S. exchange like the NYSE or NASDAQ. The club, however, remains relatively small.
Benzinga · 07/02/2021 18:22
No Data
Learn about the latest financial forecast of GWPH. Analyze the recent business situations of GW Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 10 analysts
Hold
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
10.00%Strong Buy
10.00%Buy
80.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average GWPH stock price target is 203.22 with a high estimate of 220.00 and a low estimate of 125.00.
Current 218.96
EPS
Actual
Estimate
-1.97-1.48-0.98-0.49
Institutional Holdings
Institutions: 472
Institutional Holdings: 29.31M
% Owned: 92.90%
Shares Outstanding: 31.54M
TypeInstitutionsShares
Increased
63
810.13K
New
42
1.34M
Decreased
79
1.78M
Sold Out
41
911.70K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.03%
Pharmaceuticals & Medical Research
+0.48%
Key Executives
Other
Doug Snyder
No Data
No Data
Webull offers kinds of GW Pharma stock information, including NASDAQ:GWPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GWPH stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading GWPH stock methods without spending real money on the virtual paper trading platform.